In Brief
This article was originally published in The Tan Sheet
Executive Summary
Lawmakers push energy drink investigation; Innophos buys Triarco; BASF sweetens Pronova bid; meclizine mix-up spurs iron supplement recall; Abbott Nutrition margin growth on track; Neptune’s struggles continue; Vitamin Shoppe reaches Canada; more news In Brief.
You may also be interested in...
FDA Energy Drink Plans Earn Durbin’s Stamp; Firms Meet With Agency
Senate critics say FDA “is moving forward in a number of areas to protect vulnerable populations against high levels of caffeine in energy drinks.” Monster Energy and Rockstar representatives tell FDA their products are safe. Rep. Markey asks FTC to scrutinize advertising for the products.
In Brief
BASF casts bid for Pronova BioPharma; Bayer will not top Reckitt’s Schiff bid; FDA expands arsenal against tainted supplements; CHPA launches anti-smurfing initiative; Bovine ingredients trip Atrium; more news in brief.
Harvard Drug Continues Expansion With Watson’s Rugby OTC Business
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.